王彦强，山西医科大学第五层次引进人才，博士生导师。
个人经历：2002-2006年中国农业大学生物学院获理学学士学位；2006 -2012年免试攻读中国农业大学生物化学与分子生物学专业直博研究生，获理学博士学位；2012-2017年在美国The Ohio State University的Comprehensive Cancer Center担任Postdoctoral Researcher; 2017-2019年担任Research Associate；2020年以高层次引进人才身份入职山西医科大学。
海外期间，参与多项美国国立癌症研究所 (NCI) 的研究项目 (P01CA124570 “Genes in the Predisposition to Papillary Thyroid Carcinoma” and P50CA168505 “Low-penetrance Genes in the Predisposition to Papillary Thyroid Cancer”) ，主要进行与人乳头状甲状腺癌相关的遗传易感基因及相应功能性突变的分离和鉴定工作，并对其相关分子调控机制进行解析。担任美国国家甲状腺协会（ATA）官方期刊Thyroid、Frontiers in Oncology、Frontiers in Pharmacology等学术杂志的审稿人。回国后，作为项目负责人，主持有国家自然科学基金面上项目，山西省博士后启动基金和山西医科大学高层次人才科研启动基金等科研项目。

1.    项目名称：“肿瘤遗传易感基因及驱动基因的功能和分子机制研究”；项目来源：山西医科大学特聘教授科研启动基金项目；执行年限：2020-2025；主持。
2.    项目名称：“14q13.3位点长链非编码RNA基因LINC00609和PTCSC3影响分化型甲状腺癌遗传易感性的分子机制研究”；项目来源：国家自然科学基金（82072955，面上项目）；执行年限：2021.01-2024.12；主持。
3.    项目名称：“组蛋白甲基转移酶基因在食管鳞癌中的预后意义及表达分析”；项目来源：山西省博士后启动基金项目；执行年限：2021.01-2021.12；主持。
4.    项目名称：“甲状腺癌临床诊治及基础研究创新团队“；项目来源：山西省卫生健康委员会“四个一批”科技兴医创新计划；执行年限：2021-2023；参与；基础医学方向带头人。

课程名称：肿瘤学研究热点（癌症遗传学与表观遗传学研究进展章节）
学期：秋冬
授课对象：硕士研究生。

1. Yanqiang Wang, Sandya Liyanarachchi, Katherine E. Miller, Taina T. Nieminen, Daniel F. Comiskey Jr., Wei Li, Pamela Brock, David E. Symer, Keiko Akagi, Katherine E. DeLap, Huiling He, Daniel C. Koboldt, and Albert de la Chapelle. Identification of rare variants predisposing to thyroid cancer. Thyroid. Jul;29(7): 946-955, 2019.
2. Yanqiang Wang, Huiling He, Sandya Liyanarachchi, Luke K. Genutis, Wei Li, Lianbo Yu, John Phay, Rulong Shen, Pamela Brock, and Albert de la Chapelle. The role of SMAD3 in the genetic predisposition to papillary thyroid carcinoma. Genetics in Medicine, Sep;20(9):927-935, 2018.
3. Yanqiang Wang, Huiling He, Wei Li, John Phay, Rulong Shen, Lianbo Yu, Baris Hancioglu, and Albert de la Chapelle. MYH9 binds to lncRNA gene PTCSC2 and regulates FOXE1 in the 9q22 thyroid cancer risk locus. Proceedings of The National Academy of Sciences of The United States of America. Vol. 114, 474-479, 2017.
4. Yanqiang Wang, Wei Li, John Phay, Rulong Shen, Natalia S. Pellegata, Motoyasu Saji, Matthew D. Ringel, Albert de la Chapelle, and Huiling He. Primary Cell Culture Systems for Human Thyroid Studies. Thyroid. Vol. 26, 1131-1140, 2016.
5.CDCA7 facilitates tumor progression by directly regulating CCNA2 expression in esophageal squamous cell carcinoma. Hongyi Li, Yongjia Weng, Shaojie Wang, Fang Wang, Yanqiang Wang, Pengzhou Kong, Ling Zhang, Caixia Cheng, Heyang Cui, Enwei Xu, Shuqing Wei, Dinghe Guo, Fei Chen, Yanghui Bi, Yongsheng Meng, Xiaolong Cheng and Yongping Cui. Frontiers in Oncology. 2021 Oct 19;11:734655.
6.The role of DBR1 as a candidate prognosis biomarker in esophageal squamous cell carcinoma. Xu, Xiaoqin; Yang, Xin; Liu, Xue; Bi, Yanghui; Kong, Pengzhou; Wang, Yanqiang; Cheng, Xiaolong; Xi, Yanfeng. Technology in Cancer Research & Treatment. 2022 Jan-Dec; 21.
7.Integrative Genomic Analyses of 1,145 Patient Samples Reveal New Biomarkers in Esophageal Squamous Cell Carcinoma. Binbin Zou, Dinghe Guo, Pengzhou Kong, Yanqiang Wang, Xiaolong Cheng and Yongping Cui. Front Mol Biosci. 2022 Jan 21;8:792779.
8.FAT1 downregulation enhances stemness and cisplatin resistance in esophageal squamous cell carcinoma. Yuanfang Zhai, Chengyuan Shan, Haoyu Zhang, Pengzhou Kong, Ling Zhang, Yanqiang Wang, Xiaoling Hu, Xiaolong Cheng. Mol Cell Biochem. 2022, Dec;477(12):2689-2702.
9.Elevated FAM84B promotes cell proliferation via interacting with NPM1 in esophageal squamous cell carcinoma. Fang Wang, Caixia Cheng, Xinhui Wang, Fei Chen, Hongyi Li, Yan Zhou, Yanqiang Wang, Xiaoling Hu, Pengzhou Kong, Ling Zhang, Xiaolong Cheng, Yongping Cui. Cell Death Discov. 2022 Apr 8;8(1):182.
10.CDCA7 promotes TGF-β1-induced epithelial-mesenchymal transition via transcriptionally regulating SMAD4/SMAD7 in esophageal squamous cell carcinoma. Hongyi Li, Shaojie Wang, Dinghe Guo, Yongjia Weng, Pengzhou Kong, Caixia Chen, Yanqiang Wang, Ling Zhang, Xiaolong Cheng, Yongping Cui. Cancer Science. 2023,Jan;114(1):91-104.